EP Patent

EP4066821A1 — Tablet formulations of neratinib maleate

Assigned to Wyeth LLC · Expires 2022-10-05 · 4y expired

What this patent protects

The invention provides a high strength neratinib tablet and a method of its manufacturing comprising spraying intragranular components of a granulation comprising neratinib maleate, fillers, disintegrants and glidants, with a surface modifying agent and combining them with extrag…

USPTO Abstract

The invention provides a high strength neratinib tablet and a method of its manufacturing comprising spraying intragranular components of a granulation comprising neratinib maleate, fillers, disintegrants and glidants, with a surface modifying agent and combining them with extragranular components comprising fillers, disintegrants and lubricants.

Drugs covered by this patent

Patent Metadata

Patent number
EP4066821A1
Jurisdiction
EP
Classification
—
Expires
2022-10-05
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.